Green Cross’s ‘Rixubis’ enters domestic hemophilia B market

The Green Cross and Baxalta alliance will target the hemophilia B market.

According to the industry concerned on the 9^th, Green Cross will take in charge of domestic distribution and sales of ‘Rixubis,’ a new hemophilia B treatment, as well as the hemophilia A treatment ‘Advate.’

Rixubis has been applied by the health insurance benefit since the last 1^st, and is known to be introduced at th...